Technical Data
FANCC, CT (FANCC, FAC, FACC, Fanconi anemia group C protein)
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This protein is for complementation group C.

Suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence, Flow Cytometry, ELISA

Recommended Dilution:
ELISA: 1:1,000
Western Blot: 1:100-500
Immunohistochemistry: 1:50-100
Flow Cytometry: 1:10-50
Immunofluorescence: 1:10-50

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
200ul-20CBlue IceHumanRabbit
As reported
FANCC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 529~558 amino acids from the C-terminal region of human FANCC.
Purified by Protein A affinity chromatography.
Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Barroso, E., et al. Breast Cancer Res. Treat. 118(3):655-660(2009)
McWilliams, R.R., et al. Cancer Epidemiol. Biomarkers Prev. 18(9):2549-2552(2009)
Michiels, S., et al. Carcinogenesis 30(5):763-768(2009)
Palmieri, R.T., et al. Cancer Epidemiol. Biomarkers Prev. 17(12):3567-3572(2008)
Sinha, S., et al. Mol. Cancer 7, 84 (2008) :